MedTrace Logo

A Study of MET233 in Individuals With Obesity or Overweight

NCT07022977 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2026-05-26

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity.

This study will be conducted in four parts:

* Part A will evaluate single ascending doses of MET233 or placebo.
* Part B will evaluate multiple ascending doses, with participants receiving five once-weekly doses of MET233 or placebo.
* Part C will evaluate once-weekly dosing of MET233 or placebo for 12 weeks, followed by a single higher, potential monthly dose.
* Part D will evaluate a longer dosing schedule, in which participants will receive twelve once-weekly doses, followed by three monthly doses of MET233 or placebo. Participants in this part will be followed for 14 weeks after the final dose.

Conditions

  • Obesity and Overweight

Interventions

BIOLOGICAL

MET233

For subcutaneous administration

BIOLOGICAL

Placebo

Sterile 0.9% (w/v) saline for subcutaneous administration

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-06
Primary Completion
2026-04-21
Completion
2026-04-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07022977 on ClinicalTrials.gov